← Percision · Blog

How Do We Tell a Board-Ready Growth Story in Healthtech / Digital Health?

Direct answer: Tell your growth story through a Balanced Scorecard that connects four linked perspectives — Financial, Customer/Patient, Internal Process, and Learning & Growth — so your board sees not just ARR but the clinical, operational, and regulatory drivers behind it. In healthtech specifically, that means pairing revenue metrics with outcomes data, retention by payer/provider segment, workflow adoption, and evidence-generation velocity. A story that moves only one dial (usually revenue) reads as a hope, not a strategy.

Why the Balanced Scorecard Fits Healthtech Better Than a Revenue Slide

Healthtech boards are unusually skeptical of top-line-only narratives, and for good reason. Revenue in digital health is often the lagging result of things that take quarters to move: a payer contract, a health-system integration, a peer-reviewed study, a regulatory clearance. If you show only bookings and burn, your board can't tell whether growth is durable or a one-off pilot bump.

The Balanced Scorecard, developed by Robert Kaplan and David Norton, was built to solve exactly this — the tendency to manage what's easy to count. It forces you to answer four questions in sequence:

The power is the causal chain: Learning & Growth drives Process, Process drives Customer/Patient outcomes, and those outcomes drive Financial results. A board-ready story walks that chain in reverse or forward — and shows the leading indicators that predict the lagging financial numbers.

A Concrete Walkthrough for a Digital Health Company

Here's how to populate each perspective with metrics a healthtech board actually cares about. Pick two to four per perspective — not fifteen.

1. Financial perspective

2. Customer / Patient perspective

3. Internal process perspective

4. Learning & growth perspective

The board-ready output is a single map showing how a Learning & Growth investment (say, an interoperability engineering hire) flows to a process gain (faster EHR integration), to a customer outcome (higher pilot conversion), to a financial result (ARR growth with stable margin). That's a story, not a dashboard.

How Percision Helps — and When a Spreadsheet Is Enough

Disclosure: Percision is our platform, so treat this as one option among several.

Building a rigorous Balanced Scorecard is less about the template and more about the reasoning: choosing metrics that genuinely form a causal chain, stress-testing your financial assumptions, and turning the scorecard into a plan the board can hold you to.

Percision (percision.app) is an AI strategic-intelligence platform that runs your business context through structured reasoning steps across 27+ frameworks — the Balanced Scorecard among them — to produce board-ready recommendations in minutes rather than weeks. For a healthtech growth story, it can help you draft the four-perspective map, pressure-test the financial layer with DCF and 60+ ratios, surface warning signs (margin erosion, retention concentration), and export a board deck and an Excel model with an audit trail. It's positioned as a co-pilot, not an autopilot: your leadership team decides which metrics matter and which trade-offs to make. Broader research — including a 2023 Harvard Business School / BCG field study — suggests generative AI meaningfully improves output on well-structured knowledge tasks, though the same study warns of a "jagged frontier" where AI performs worse on tasks outside its strengths. Judgment stays human.

When you don't need it: if you already have a finance lead who can build the scorecard in a spreadsheet and a strategy partner to challenge assumptions, that may be entirely sufficient — especially for a single planning cycle. If your challenge is deep regulatory or reimbursement strategy specific to a therapeutic area, a specialist human consultant will outperform any general tool. Use Percision when you want consulting-grade structure fast, or as a first draft to hand your team; use people and spreadsheets when the problem is narrow, deeply domain-specific, or already well-owned internally.

Whichever path you choose, the discipline is the same: connect the chain, show the leading indicators, and be honest about the metric that isn't moving yet.

If you want to pressure-test your scorecard and generate a board deck quickly, you can try Percision here.

What this looks like when the analysis is actually run

A board that has ruled out a priced round needs a story about margin and retention, not about bookings.

The subject is Vantabridge Health, a sample company profile we use for testing rather than a customer: a virtual chronic-care platform, $62M revenue, 340,000 enrolled members.

Excerpt from a real Percision run · Quick Market Scan (T1) · sample company profile

The constraint stated first. Funded entirely from the existing $48M cash runway at a $14M annual burn; the board has ruled out a priced round in FY2026.

The revenue story, which is mostly defensive. $62.0M ARR flat in Year 1 — preventing further decline; $64.5M in Year 2, up 4% via retention of two plans that would have churned; $67.0M in Year 3, up 4% via a 25% at-risk cap enabling three new plan expansions. The engine prevents 9% logo churn from rising to 12%.

The margin story. Gross margin uplift of 8–11 percentage points, from 54% to 62–65%, by Month 18 — $11–15M of annual margin uplift from automating 25–35% of gross-margin leakage.

The growth story alongside it. $11.7M of cumulative incremental employer revenue by Month 24 on $0.6–0.9M — a 13.0× return.

What both cost. $2.1–2.8M and $0.6–0.9M respectively, against $48M of cash.

The retention numbers behind the revenue line. Health-plan logo churn on the engine cohort at 6% or better against a current 9%; at-risk share in renewal contracts at 25% or below by Month 12, protecting $5.9M of annual at-risk revenue out of $23.6M; outcomes-reconciliation cycle time at 30 days or less by Month 6; employer engagement at 45% or better against 41%. Employer revenue reaches $3.9M by Month 12 and $18.5M cumulative in Year 3 at 15% YoY cohort growth.

Go / no-go gates before the next phase is funded
PhaseGate metricTargetDeadline
Foundation (Q3-Q4 2026)Pilot engine produces validated 12-month outcomes for 5 plans within 30 days of measurement close with <5% variance vs manual audit≥95% match rateMonth 6
Traction (Q1-Q2 2027)8 renewal contracts signed at 25% at-risk cap with zero logo churn on those accounts≥8 contractsMonth 12
Scale (Q3-Q4 2027)3 net-new health-plan logos signed at $1.82M ARR each with engine embedded in contract≥3 logosMonth 18

Year 1 ARR is flat and the plan says so in the first line — described as preventing further decline rather than as growth. For a company whose growth has fallen from 42% to 13% and which cannot raise, that is the honest framing and the one the board can act on.

The margin story carries the case. Eight to eleven points of gross margin on $62M is worth more than any plausible bookings number, and unlike bookings it does not depend on a procurement cycle. A company that cannot raise has to buy time with margin, and that is what this is.

Read a complete Percision report — every page, no email required.

FAQ

Q: How many metrics should a healthtech Balanced Scorecard have? Aim for 8–16 total — two to four per perspective. More than that and the board loses the narrative; the point is the causal chain, not exhaustive reporting.

Q: What's the one metric healthtech boards under-weight? Clinical outcomes evidence. It sits in the Customer/Patient layer but is the leading indicator payers use to justify contracts — and therefore the truest predictor of durable revenue.

Q: Can we build this without an AI tool or consultant? Yes. If you have finance and strategy capacity in-house, a spreadsheet and a disciplined workshop are enough. Tools and consultants add value when you need speed, external rigor, or a defensible financial model to accompany the story.

Ready to run this on your company?
A free Percision diagnostic turns the analysis into a decision with owners and numbers — one click from this article.
Run the free diagnostic →
Get the full State of AI Strategy 2026 report
The research, the method, and the pre-registered tests — plus occasional notes on governed AI strategy. No spam; unsubscribe anytime.